Regulators at the FDA have reiterated concerns that Replimmune does not have adequate data to support an approval of its ...

One year after launching the CMS Health Tech Ecosystem, officials convened in D.C. to celebrate the Trump administration ...

The big takeaway from the recent Alzheimer’s Association International Conference in London is an economic message: Dementia ...

The world risks a resurgence of the HIV epidemic after international financing to combat the disease suffered a “profound ...

Emergency departments across America report dramatic increases in serious injuries from e-bikes and e-scooters,” write CHOP’s ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Rarely has a new technology so squarely ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. Sarepta Therapeutics, the bruised ...

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another ...

In a win for peptide proponents, an FDA advisory panel recommended compounding pharmacies be allowed to make four of the ...

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Sarepta Therapeutics’ CEO Doug Ingram said ...

Chelsea covers the Department of Health and Human Services with a particular focus on power and influence at the top. Confidential tips can be sent via Signal at chelseacirruzzo.42. WASHINGTON — The ...

Oak Hill Bio, a new company backed by RA Capital and other investors, will take on Ultragenyx and Ionis in developing an ...